Navigation Links
ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
Date:5/29/2008

e-blind, placebo-controlled, multicenter pivotal Phase 3 study in 681 patients who have undergone allogeneic stem cell transplantation. Following transplantation and transplant engraftment, eligible patients have been randomized to receive maribavir or matching placebo in a 2:1 randomization ratio. All patients will receive maribavir 100 mg BID or placebo for a maximum duration of 12 weeks, and will then be followed for an additional 12 weeks to reach the 6-month post-transplant analyses for regulatory filing purposes. All patients will then be followed for an additional 24 weeks.

Enrolled subjects will undergo testing for CMV infection at least weekly. CMV surveillance includes weekly testing at a central laboratory for the presence of CMV pp65 antigenemia and for the presence of CMV DNA in plasma using a polymerase chain reaction (PCR). If CMV infection is detected during the study drug administration period (or if CMV organ disease is diagnosed), study drug will be discontinued and the subject will be managed according to standard CMV treatment practices at the transplant center.

The primary efficacy endpoint will be the incidence of CMV disease within six months post-transplant, which is predicted to be approximately nine percent in the placebo (current standard of care) arm based on data from the Phase 2 study, data from published literature, and information from transplant center databases. Following extensive dialogue with FDA, a number of key secondary endpoints associated with CMV infection have been identified and assessment of these endpoints will be essential in assessing the clinical benefit of maribavir. These key secondary endpoints include incidence of initiation of preemptive anti-CMV therapy, incidence of graft-versus-host disease, mortality and CMV disease-free survival.

About maribavir

Maribavir is a potent and selective, orally bioavailable Phase 3 antiviral drug with a unique mechanism of action against cytomegalovir
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma Announces Discontinuation of HCV-796 Development
2. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Present at the Natixis Bleichroeder Conference
5. ViroPharma to Present at Three Upcoming Healthcare Conferences
6. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
9. Genmab Announces Updates on Phase III Cancer Studies
10. Kiadis Pharma Announces Collaboration With the Julius Maximilians University of Wurzburg, Germany
11. Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015  In a sweeping analysis assessing ... T1D Exchange researchers conclude that there remains ... diabetes across all age groups, but especially for adolescents ... picture of diabetes treatment, underscoring the need to address ... that can help type 1 patients achieve optimal metabolic ...
(Date:5/22/2015)... , May 22, 2015 AcelRx Pharmaceuticals, Inc. ... on the development and commercialization of innovative therapies for ... that interim chief executive officer Howie Rosen ... chief financial officer Tim Morris will be ... the two presentations are as follows: Jefferies ...
(Date:5/21/2015)... , May 21, 2015 ... ) has announced the addition of the ... Type (Ankle Replacement, Digit Replacement, Elbow Replacement, ... Forecast to 2019" report to their ... for knee replacement was valued at $4,470.9 ...
Breaking Medicine Technology:Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2
... , ROCKVILLE, Md., Dec. 9 Novavax, ... 25, 2009, it closed its previously announced public offering of ... Novavax received net proceeds from the sale of the ... approximately $21 million, which will be used for preclinical studies ...
... , GAITHERSBURG, Md, Dec. 9 Lentigen Corporation, ... of lentiviral gene delivery technologies, announced today that it ... business innovation research (SBIR) grant for a program on ... using Lentivirus". In this program, Lentigen will collaborate ...
Cached Medicine Technology:NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock 2Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2
(Date:5/23/2015)... With the implementation of the Affordable Care ... difficult to provide their employees with a viable healthcare ... for employees stand to face strict penalties. Never before ... of a business’s success or failure. In an effort ... Doctors has created a varying level of less expensive ...
(Date:5/23/2015)... May 23, 2015 Javon Bea ... the Sports Medicine and Rehabilitation Center, 557 N. Washington ... Mondays, June 1-July 20, 5:30-6:30 pm. , The 8-week ... and Laurie Finke, RN, BSN, who will offer training ... on nutrition, running mechanics and show selection and weekly ...
(Date:5/22/2015)... May 22, 2015 The American College ... events in June. They will hold a webinar on ... a two-day class on Classical Chinese Medicine. , Webinar ... Dr. Steve Given, the Dean of Clinical Education, will ... new First Professional Doctorate program. ACTCM is currently developing ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Omar Ahmad ... selected to participate in the 2015 Congress of Future ... described as a gathering of “America’s highest achieving high ... areas of healthcare, set new goals and learn better ... a live surgery, during which we can ask the ...
(Date:5/22/2015)... Pa (PRWEB) May 22, 2015 ... (AHN) today announced a new partnership to develop ... for the region. The initiative includes a new exhibit ... live demonstration theater, and a new traveling science ... the fall of 2015. , Designed to explore ...
Breaking Medicine News(10 mins):Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:ACTCM Announces Upcoming June Events 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4
... , Jan. 13 WellPoint, Inc. (NYSE: ... a "2010 Diversity Leader Award®" in the January/February issue of ... communication practices during the past year. , WellPoint continues ... inclusion practices and has received multiple honors in recent years ...
... ... products direct to patients which will reduce operating costs for providers and improve patient ... Plainview, ... announced today a strategic alliance designed to automate the shipping of CPAP products ...
... ... your health , ... the gym and cheaper than cosmetic surgery or even your nighttime moisturizer, turning up the heat ... and your health., , , , ,“An active sex life will make you healthier, buffer, younger ...
... ... advertising executive launches RedSquare360 to accommodate manufacturers, and web retailers, growing demands for 3D ... to help ecommerce clients increase conversion rates. , ... (PRWEB) January 13, 2010 -- Online retailers know the ...
... ... Microbix will maintain sales and marketing functions while Therapure will manage manufacturing, distribution ... ... Biosystems Inc. (MBX:TSX) a biotechnology company focused on virology and biological technologies, and ...
... ... firm striving to help families with wide range of legal needs. , ... New Brunswick, N.J. (Lexis Nexis) January 13, 2010 ... resources and skilled legal professionals that will help them navigate the state,s court system, ...
Cached Medicine News:Health News:WellPoint, Inc. Receives 2010 Diversity Leader Award(R) 2Health News:WellPoint, Inc. Receives 2010 Diversity Leader Award(R) 3Health News:Fastrack & cpapdropship.com Form Alliance to Reduce Provider Costs 2Health News:Fastrack & cpapdropship.com Form Alliance to Reduce Provider Costs 3Health News:Frequent and Fabulous Sex -- A Menopausal Woman's Surprising Fountain of Youth 2Health News:Frequent and Fabulous Sex -- A Menopausal Woman's Surprising Fountain of Youth 3Health News:360 Images Give Online Consumers A Product 'Demo' Before Purchasing. 2Health News:360 Images Give Online Consumers A Product 'Demo' Before Purchasing. 3Health News:Microbix and Therapure Biopharma Form Partnership to Expand Water-Based Supplies to the Pharma Industry 2Health News:Microbix and Therapure Biopharma Form Partnership to Expand Water-Based Supplies to the Pharma Industry 3Health News:Shamy & Shamy Launches New Web Site Providing Simple Access to Free Online Resources for New Jersey Court System 2
Serology provides a minimally-invasive, sensitive and easy-to-perform method for the determination of H. pylori infection. The Bio-Rad H. pylori qualitative test kits use EIA technology for the deter...
... effective and relatively bloodless procedure for immediate ... to learn and can be performed in ... setting with few if any patient complications. ... OR time and use a familiar technology ...
... IFA Test kit is a user-friendly ... in dropper bottles. A single monoclonal ... identify all serogroups of L. pneumophilia ... culture isolates, confirming a diagnosis of ...
... of the most innovative and elegantly simple ... provides an ideal solution for physicians seeking ... other option provides a better combination of ... System heats, circulates, and maintains precise control ...
Medicine Products: